Global Generic and Biosimilar Pharmaceuticals Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Generic and Biosimilar Pharmaceuticals market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Generic and Biosimilar Pharmaceuticals market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Generic and Biosimilar Pharmaceuticals market size and forecasts, in consumption value ($ Million), 2018-2029
Global Generic and Biosimilar Pharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Generic and Biosimilar Pharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Generic and Biosimilar Pharmaceuticals market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Generic and Biosimilar Pharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Generic and Biosimilar Pharmaceuticals market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi-Aventis and Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Generic and Biosimilar Pharmaceuticals market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Generic and Biosimilar Pharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Generic and Biosimilar Pharmaceuticals, with revenue, gross margin and global market share of Generic and Biosimilar Pharmaceuticals from 2018 to 2023.
Chapter 3, the Generic and Biosimilar Pharmaceuticals competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Generic and Biosimilar Pharmaceuticals market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Generic and Biosimilar Pharmaceuticals.
Chapter 13, to describe Generic and Biosimilar Pharmaceuticals research findings and conclusion.
This report is a detailed and comprehensive analysis for global Generic and Biosimilar Pharmaceuticals market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Generic and Biosimilar Pharmaceuticals market size and forecasts, in consumption value ($ Million), 2018-2029
Global Generic and Biosimilar Pharmaceuticals market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Generic and Biosimilar Pharmaceuticals market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Generic and Biosimilar Pharmaceuticals market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Generic and Biosimilar Pharmaceuticals
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Generic and Biosimilar Pharmaceuticals market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi-Aventis and Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Generic and Biosimilar Pharmaceuticals market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Other
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Other
- Roche
- Amgen
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- 3sbio
- Changchun High Tech
- CP Guojian
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Generic and Biosimilar Pharmaceuticals product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Generic and Biosimilar Pharmaceuticals, with revenue, gross margin and global market share of Generic and Biosimilar Pharmaceuticals from 2018 to 2023.
Chapter 3, the Generic and Biosimilar Pharmaceuticals competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Generic and Biosimilar Pharmaceuticals market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Generic and Biosimilar Pharmaceuticals.
Chapter 13, to describe Generic and Biosimilar Pharmaceuticals research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Generic and Biosimilar Pharmaceuticals
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Generic and Biosimilar Pharmaceuticals by Type
1.3.1 Overview: Global Generic and Biosimilar Pharmaceuticals Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type in 2022
1.3.3 Monoclonal Antibodies
1.3.4 Interferon
1.3.5 Erythropoietin
1.3.6 Insulin
1.3.7 Vaccines
1.3.8 Other
1.4 Global Generic and Biosimilar Pharmaceuticals Market by Application
1.4.1 Overview: Global Generic and Biosimilar Pharmaceuticals Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Tumor
1.4.3 Diabetes
1.4.4 Cardiovascular
1.4.5 Hemophilia
1.4.6 Other
1.5 Global Generic and Biosimilar Pharmaceuticals Market Size & Forecast
1.6 Global Generic and Biosimilar Pharmaceuticals Market Size and Forecast by Region
1.6.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Generic and Biosimilar Pharmaceuticals Market Size by Region, (2018-2029)
1.6.3 North America Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.4 Europe Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.6 South America Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Generic and Biosimilar Pharmaceuticals Product and Solutions
2.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Generic and Biosimilar Pharmaceuticals Product and Solutions
2.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Recent Developments and Future Plans
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Product and Solutions
2.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 AbbVie Recent Developments and Future Plans
2.4 Sanofi-Aventis
2.4.1 Sanofi-Aventis Details
2.4.2 Sanofi-Aventis Major Business
2.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product and Solutions
2.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sanofi-Aventis Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product and Solutions
2.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Product and Solutions
2.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business
2.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Product and Solutions
2.7.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novo Nordisk Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Product and Solutions
2.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Generic and Biosimilar Pharmaceuticals Product and Solutions
2.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Novartis Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Generic and Biosimilar Pharmaceuticals Product and Solutions
2.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Merck Recent Developments and Future Plans
2.11 3sbio
2.11.1 3sbio Details
2.11.2 3sbio Major Business
2.11.3 3sbio Generic and Biosimilar Pharmaceuticals Product and Solutions
2.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 3sbio Recent Developments and Future Plans
2.12 Changchun High Tech
2.12.1 Changchun High Tech Details
2.12.2 Changchun High Tech Major Business
2.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Product and Solutions
2.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Changchun High Tech Recent Developments and Future Plans
2.13 CP Guojian
2.13.1 CP Guojian Details
2.13.2 CP Guojian Major Business
2.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Product and Solutions
2.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 CP Guojian Recent Developments and Future Plans
2.14 Biotech
2.14.1 Biotech Details
2.14.2 Biotech Major Business
2.14.3 Biotech Generic and Biosimilar Pharmaceuticals Product and Solutions
2.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Biotech Recent Developments and Future Plans
2.15 Gelgen
2.15.1 Gelgen Details
2.15.2 Gelgen Major Business
2.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Product and Solutions
2.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Gelgen Recent Developments and Future Plans
2.16 Innovent
2.16.1 Innovent Details
2.16.2 Innovent Major Business
2.16.3 Innovent Generic and Biosimilar Pharmaceuticals Product and Solutions
2.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Innovent Recent Developments and Future Plans
2.17 Dong Bao
2.17.1 Dong Bao Details
2.17.2 Dong Bao Major Business
2.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Product and Solutions
2.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Dong Bao Recent Developments and Future Plans
2.18 Ganlee
2.18.1 Ganlee Details
2.18.2 Ganlee Major Business
2.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Product and Solutions
2.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Ganlee Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Generic and Biosimilar Pharmaceuticals Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Generic and Biosimilar Pharmaceuticals by Company Revenue
3.2.2 Top 3 Generic and Biosimilar Pharmaceuticals Players Market Share in 2022
3.2.3 Top 6 Generic and Biosimilar Pharmaceuticals Players Market Share in 2022
3.3 Generic and Biosimilar Pharmaceuticals Market: Overall Company Footprint Analysis
3.3.1 Generic and Biosimilar Pharmaceuticals Market: Region Footprint
3.3.2 Generic and Biosimilar Pharmaceuticals Market: Company Product Type Footprint
3.3.3 Generic and Biosimilar Pharmaceuticals Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Generic and Biosimilar Pharmaceuticals Consumption Value and Market Share by Type (2018-2023)
4.2 Global Generic and Biosimilar Pharmaceuticals Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2023)
5.2 Global Generic and Biosimilar Pharmaceuticals Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
6.2 North America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
6.3 North America Generic and Biosimilar Pharmaceuticals Market Size by Country
6.3.1 North America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
6.3.2 United States Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
6.3.3 Canada Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
6.3.4 Mexico Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
7.2 Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
7.3 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country
7.3.1 Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
7.3.2 Germany Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.3 France Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.5 Russia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.6 Italy Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region
8.3.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2018-2029)
8.3.2 China Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.3 Japan Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.4 South Korea Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.5 India Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.7 Australia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
9.2 South America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
9.3 South America Generic and Biosimilar Pharmaceuticals Market Size by Country
9.3.1 South America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
9.3.2 Brazil Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
9.3.3 Argentina Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country
10.3.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
10.3.2 Turkey Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
10.3.4 UAE Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Generic and Biosimilar Pharmaceuticals Market Drivers
11.2 Generic and Biosimilar Pharmaceuticals Market Restraints
11.3 Generic and Biosimilar Pharmaceuticals Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Generic and Biosimilar Pharmaceuticals Industry Chain
12.2 Generic and Biosimilar Pharmaceuticals Upstream Analysis
12.3 Generic and Biosimilar Pharmaceuticals Midstream Analysis
12.4 Generic and Biosimilar Pharmaceuticals Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Generic and Biosimilar Pharmaceuticals
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Generic and Biosimilar Pharmaceuticals by Type
1.3.1 Overview: Global Generic and Biosimilar Pharmaceuticals Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type in 2022
1.3.3 Monoclonal Antibodies
1.3.4 Interferon
1.3.5 Erythropoietin
1.3.6 Insulin
1.3.7 Vaccines
1.3.8 Other
1.4 Global Generic and Biosimilar Pharmaceuticals Market by Application
1.4.1 Overview: Global Generic and Biosimilar Pharmaceuticals Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Tumor
1.4.3 Diabetes
1.4.4 Cardiovascular
1.4.5 Hemophilia
1.4.6 Other
1.5 Global Generic and Biosimilar Pharmaceuticals Market Size & Forecast
1.6 Global Generic and Biosimilar Pharmaceuticals Market Size and Forecast by Region
1.6.1 Global Generic and Biosimilar Pharmaceuticals Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Generic and Biosimilar Pharmaceuticals Market Size by Region, (2018-2029)
1.6.3 North America Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.4 Europe Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.6 South America Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Generic and Biosimilar Pharmaceuticals Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Generic and Biosimilar Pharmaceuticals Product and Solutions
2.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Generic and Biosimilar Pharmaceuticals Product and Solutions
2.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Recent Developments and Future Plans
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Product and Solutions
2.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 AbbVie Recent Developments and Future Plans
2.4 Sanofi-Aventis
2.4.1 Sanofi-Aventis Details
2.4.2 Sanofi-Aventis Major Business
2.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product and Solutions
2.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sanofi-Aventis Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product and Solutions
2.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Product and Solutions
2.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business
2.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Product and Solutions
2.7.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novo Nordisk Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Product and Solutions
2.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Generic and Biosimilar Pharmaceuticals Product and Solutions
2.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Novartis Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Generic and Biosimilar Pharmaceuticals Product and Solutions
2.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Merck Recent Developments and Future Plans
2.11 3sbio
2.11.1 3sbio Details
2.11.2 3sbio Major Business
2.11.3 3sbio Generic and Biosimilar Pharmaceuticals Product and Solutions
2.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 3sbio Recent Developments and Future Plans
2.12 Changchun High Tech
2.12.1 Changchun High Tech Details
2.12.2 Changchun High Tech Major Business
2.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Product and Solutions
2.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Changchun High Tech Recent Developments and Future Plans
2.13 CP Guojian
2.13.1 CP Guojian Details
2.13.2 CP Guojian Major Business
2.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Product and Solutions
2.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 CP Guojian Recent Developments and Future Plans
2.14 Biotech
2.14.1 Biotech Details
2.14.2 Biotech Major Business
2.14.3 Biotech Generic and Biosimilar Pharmaceuticals Product and Solutions
2.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Biotech Recent Developments and Future Plans
2.15 Gelgen
2.15.1 Gelgen Details
2.15.2 Gelgen Major Business
2.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Product and Solutions
2.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Gelgen Recent Developments and Future Plans
2.16 Innovent
2.16.1 Innovent Details
2.16.2 Innovent Major Business
2.16.3 Innovent Generic and Biosimilar Pharmaceuticals Product and Solutions
2.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Innovent Recent Developments and Future Plans
2.17 Dong Bao
2.17.1 Dong Bao Details
2.17.2 Dong Bao Major Business
2.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Product and Solutions
2.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Dong Bao Recent Developments and Future Plans
2.18 Ganlee
2.18.1 Ganlee Details
2.18.2 Ganlee Major Business
2.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Product and Solutions
2.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Ganlee Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Generic and Biosimilar Pharmaceuticals Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Generic and Biosimilar Pharmaceuticals by Company Revenue
3.2.2 Top 3 Generic and Biosimilar Pharmaceuticals Players Market Share in 2022
3.2.3 Top 6 Generic and Biosimilar Pharmaceuticals Players Market Share in 2022
3.3 Generic and Biosimilar Pharmaceuticals Market: Overall Company Footprint Analysis
3.3.1 Generic and Biosimilar Pharmaceuticals Market: Region Footprint
3.3.2 Generic and Biosimilar Pharmaceuticals Market: Company Product Type Footprint
3.3.3 Generic and Biosimilar Pharmaceuticals Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Generic and Biosimilar Pharmaceuticals Consumption Value and Market Share by Type (2018-2023)
4.2 Global Generic and Biosimilar Pharmaceuticals Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2023)
5.2 Global Generic and Biosimilar Pharmaceuticals Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
6.2 North America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
6.3 North America Generic and Biosimilar Pharmaceuticals Market Size by Country
6.3.1 North America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
6.3.2 United States Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
6.3.3 Canada Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
6.3.4 Mexico Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
7.2 Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
7.3 Europe Generic and Biosimilar Pharmaceuticals Market Size by Country
7.3.1 Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
7.3.2 Germany Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.3 France Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.5 Russia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
7.3.6 Italy Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals Market Size by Region
8.3.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2018-2029)
8.3.2 China Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.3 Japan Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.4 South Korea Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.5 India Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
8.3.7 Australia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
9.2 South America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
9.3 South America Generic and Biosimilar Pharmaceuticals Market Size by Country
9.3.1 South America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
9.3.2 Brazil Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
9.3.3 Argentina Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Generic and Biosimilar Pharmaceuticals Market Size by Country
10.3.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2029)
10.3.2 Turkey Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
10.3.4 UAE Generic and Biosimilar Pharmaceuticals Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Generic and Biosimilar Pharmaceuticals Market Drivers
11.2 Generic and Biosimilar Pharmaceuticals Market Restraints
11.3 Generic and Biosimilar Pharmaceuticals Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Generic and Biosimilar Pharmaceuticals Industry Chain
12.2 Generic and Biosimilar Pharmaceuticals Upstream Analysis
12.3 Generic and Biosimilar Pharmaceuticals Midstream Analysis
12.4 Generic and Biosimilar Pharmaceuticals Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 8. Roche Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Roche Recent Developments and Future Plans
Table 10. Amgen Company Information, Head Office, and Major Competitors
Table 11. Amgen Major Business
Table 12. Amgen Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 13. Amgen Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Amgen Recent Developments and Future Plans
Table 15. AbbVie Company Information, Head Office, and Major Competitors
Table 16. AbbVie Major Business
Table 17. AbbVie Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 18. AbbVie Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. AbbVie Recent Developments and Future Plans
Table 20. Sanofi-Aventis Company Information, Head Office, and Major Competitors
Table 21. Sanofi-Aventis Major Business
Table 22. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 23. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Sanofi-Aventis Recent Developments and Future Plans
Table 25. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson Major Business
Table 27. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 28. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Johnson & Johnson Recent Developments and Future Plans
Table 30. Pfizer Company Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 33. Pfizer Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Pfizer Recent Developments and Future Plans
Table 35. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 36. Novo Nordisk Major Business
Table 37. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 38. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novo Nordisk Recent Developments and Future Plans
Table 40. Eli Lilly Company Information, Head Office, and Major Competitors
Table 41. Eli Lilly Major Business
Table 42. Eli Lilly Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 43. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Eli Lilly Recent Developments and Future Plans
Table 45. Novartis Company Information, Head Office, and Major Competitors
Table 46. Novartis Major Business
Table 47. Novartis Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 48. Novartis Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Novartis Recent Developments and Future Plans
Table 50. Merck Company Information, Head Office, and Major Competitors
Table 51. Merck Major Business
Table 52. Merck Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 53. Merck Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Merck Recent Developments and Future Plans
Table 55. 3sbio Company Information, Head Office, and Major Competitors
Table 56. 3sbio Major Business
Table 57. 3sbio Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 58. 3sbio Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. 3sbio Recent Developments and Future Plans
Table 60. Changchun High Tech Company Information, Head Office, and Major Competitors
Table 61. Changchun High Tech Major Business
Table 62. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 63. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Changchun High Tech Recent Developments and Future Plans
Table 65. CP Guojian Company Information, Head Office, and Major Competitors
Table 66. CP Guojian Major Business
Table 67. CP Guojian Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 68. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. CP Guojian Recent Developments and Future Plans
Table 70. Biotech Company Information, Head Office, and Major Competitors
Table 71. Biotech Major Business
Table 72. Biotech Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 73. Biotech Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Biotech Recent Developments and Future Plans
Table 75. Gelgen Company Information, Head Office, and Major Competitors
Table 76. Gelgen Major Business
Table 77. Gelgen Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 78. Gelgen Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Gelgen Recent Developments and Future Plans
Table 80. Innovent Company Information, Head Office, and Major Competitors
Table 81. Innovent Major Business
Table 82. Innovent Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 83. Innovent Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Innovent Recent Developments and Future Plans
Table 85. Dong Bao Company Information, Head Office, and Major Competitors
Table 86. Dong Bao Major Business
Table 87. Dong Bao Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 88. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Dong Bao Recent Developments and Future Plans
Table 90. Ganlee Company Information, Head Office, and Major Competitors
Table 91. Ganlee Major Business
Table 92. Ganlee Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 93. Ganlee Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Ganlee Recent Developments and Future Plans
Table 95. Global Generic and Biosimilar Pharmaceuticals Revenue (USD Million) by Players (2018-2023)
Table 96. Global Generic and Biosimilar Pharmaceuticals Revenue Share by Players (2018-2023)
Table 97. Breakdown of Generic and Biosimilar Pharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3)
Table 98. Market Position of Players in Generic and Biosimilar Pharmaceuticals, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 99. Head Office of Key Generic and Biosimilar Pharmaceuticals Players
Table 100. Generic and Biosimilar Pharmaceuticals Market: Company Product Type Footprint
Table 101. Generic and Biosimilar Pharmaceuticals Market: Company Product Application Footprint
Table 102. Generic and Biosimilar Pharmaceuticals New Market Entrants and Barriers to Market Entry
Table 103. Generic and Biosimilar Pharmaceuticals Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Generic and Biosimilar Pharmaceuticals Consumption Value (USD Million) by Type (2018-2023)
Table 105. Global Generic and Biosimilar Pharmaceuticals Consumption Value Share by Type (2018-2023)
Table 106. Global Generic and Biosimilar Pharmaceuticals Consumption Value Forecast by Type (2024-2029)
Table 107. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023)
Table 108. Global Generic and Biosimilar Pharmaceuticals Consumption Value Forecast by Application (2024-2029)
Table 109. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 110. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 111. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 112. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 113. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 114. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 115. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 118. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 119. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 122. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 123. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 124. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 125. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2018-2023) & (USD Million)
Table 126. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2024-2029) & (USD Million)
Table 127. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 128. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 129. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 130. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 131. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 132. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 134. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 135. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 136. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 137. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 138. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 139. Generic and Biosimilar Pharmaceuticals Raw Material
Table 140. Key Suppliers of Generic and Biosimilar Pharmaceuticals Raw Materials
Table 1. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 8. Roche Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Roche Recent Developments and Future Plans
Table 10. Amgen Company Information, Head Office, and Major Competitors
Table 11. Amgen Major Business
Table 12. Amgen Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 13. Amgen Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Amgen Recent Developments and Future Plans
Table 15. AbbVie Company Information, Head Office, and Major Competitors
Table 16. AbbVie Major Business
Table 17. AbbVie Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 18. AbbVie Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. AbbVie Recent Developments and Future Plans
Table 20. Sanofi-Aventis Company Information, Head Office, and Major Competitors
Table 21. Sanofi-Aventis Major Business
Table 22. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 23. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Sanofi-Aventis Recent Developments and Future Plans
Table 25. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson Major Business
Table 27. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 28. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Johnson & Johnson Recent Developments and Future Plans
Table 30. Pfizer Company Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 33. Pfizer Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Pfizer Recent Developments and Future Plans
Table 35. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 36. Novo Nordisk Major Business
Table 37. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 38. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novo Nordisk Recent Developments and Future Plans
Table 40. Eli Lilly Company Information, Head Office, and Major Competitors
Table 41. Eli Lilly Major Business
Table 42. Eli Lilly Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 43. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Eli Lilly Recent Developments and Future Plans
Table 45. Novartis Company Information, Head Office, and Major Competitors
Table 46. Novartis Major Business
Table 47. Novartis Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 48. Novartis Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Novartis Recent Developments and Future Plans
Table 50. Merck Company Information, Head Office, and Major Competitors
Table 51. Merck Major Business
Table 52. Merck Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 53. Merck Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Merck Recent Developments and Future Plans
Table 55. 3sbio Company Information, Head Office, and Major Competitors
Table 56. 3sbio Major Business
Table 57. 3sbio Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 58. 3sbio Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. 3sbio Recent Developments and Future Plans
Table 60. Changchun High Tech Company Information, Head Office, and Major Competitors
Table 61. Changchun High Tech Major Business
Table 62. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 63. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Changchun High Tech Recent Developments and Future Plans
Table 65. CP Guojian Company Information, Head Office, and Major Competitors
Table 66. CP Guojian Major Business
Table 67. CP Guojian Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 68. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. CP Guojian Recent Developments and Future Plans
Table 70. Biotech Company Information, Head Office, and Major Competitors
Table 71. Biotech Major Business
Table 72. Biotech Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 73. Biotech Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Biotech Recent Developments and Future Plans
Table 75. Gelgen Company Information, Head Office, and Major Competitors
Table 76. Gelgen Major Business
Table 77. Gelgen Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 78. Gelgen Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Gelgen Recent Developments and Future Plans
Table 80. Innovent Company Information, Head Office, and Major Competitors
Table 81. Innovent Major Business
Table 82. Innovent Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 83. Innovent Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Innovent Recent Developments and Future Plans
Table 85. Dong Bao Company Information, Head Office, and Major Competitors
Table 86. Dong Bao Major Business
Table 87. Dong Bao Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 88. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Dong Bao Recent Developments and Future Plans
Table 90. Ganlee Company Information, Head Office, and Major Competitors
Table 91. Ganlee Major Business
Table 92. Ganlee Generic and Biosimilar Pharmaceuticals Product and Solutions
Table 93. Ganlee Generic and Biosimilar Pharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Ganlee Recent Developments and Future Plans
Table 95. Global Generic and Biosimilar Pharmaceuticals Revenue (USD Million) by Players (2018-2023)
Table 96. Global Generic and Biosimilar Pharmaceuticals Revenue Share by Players (2018-2023)
Table 97. Breakdown of Generic and Biosimilar Pharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3)
Table 98. Market Position of Players in Generic and Biosimilar Pharmaceuticals, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 99. Head Office of Key Generic and Biosimilar Pharmaceuticals Players
Table 100. Generic and Biosimilar Pharmaceuticals Market: Company Product Type Footprint
Table 101. Generic and Biosimilar Pharmaceuticals Market: Company Product Application Footprint
Table 102. Generic and Biosimilar Pharmaceuticals New Market Entrants and Barriers to Market Entry
Table 103. Generic and Biosimilar Pharmaceuticals Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Generic and Biosimilar Pharmaceuticals Consumption Value (USD Million) by Type (2018-2023)
Table 105. Global Generic and Biosimilar Pharmaceuticals Consumption Value Share by Type (2018-2023)
Table 106. Global Generic and Biosimilar Pharmaceuticals Consumption Value Forecast by Type (2024-2029)
Table 107. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023)
Table 108. Global Generic and Biosimilar Pharmaceuticals Consumption Value Forecast by Application (2024-2029)
Table 109. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 110. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 111. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 112. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 113. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 114. North America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 115. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 118. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 119. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 122. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 123. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 124. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 125. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2018-2023) & (USD Million)
Table 126. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value by Region (2024-2029) & (USD Million)
Table 127. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 128. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 129. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 130. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 131. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 132. South America Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2018-2023) & (USD Million)
Table 134. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Type (2024-2029) & (USD Million)
Table 135. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2018-2023) & (USD Million)
Table 136. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Application (2024-2029) & (USD Million)
Table 137. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2018-2023) & (USD Million)
Table 138. Middle East & Africa Generic and Biosimilar Pharmaceuticals Consumption Value by Country (2024-2029) & (USD Million)
Table 139. Generic and Biosimilar Pharmaceuticals Raw Material
Table 140. Key Suppliers of Generic and Biosimilar Pharmaceuticals Raw Materials
LIST OF FIGURES
Figure 1. Generic and Biosimilar Pharmaceuticals Picture
Figure 2. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type in 2022
Figure 4. Monoclonal Antibodies
Figure 5. Interferon
Figure 6. Erythropoietin
Figure 7. Insulin
Figure 8. Vaccines
Figure 9. Other
Figure 10. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 11. Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application in 2022
Figure 12. Tumor Picture
Figure 13. Diabetes Picture
Figure 14. Cardiovascular Picture
Figure 15. Hemophilia Picture
Figure 16. Other Picture
Figure 17. Global Generic and Biosimilar Pharmaceuticals Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 18. Global Generic and Biosimilar Pharmaceuticals Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 19. Global Market Generic and Biosimilar Pharmaceuticals Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 20. Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Region (2018-2029)
Figure 21. Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Region in 2022
Figure 22. North America Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Generic and Biosimilar Pharmaceuticals Revenue Share by Players in 2022
Figure 28. Generic and Biosimilar Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 29. Global Top 3 Players Generic and Biosimilar Pharmaceuticals Market Share in 2022
Figure 30. Global Top 6 Players Generic and Biosimilar Pharmaceuticals Market Share in 2022
Figure 31. Global Generic and Biosimilar Pharmaceuticals Consumption Value Share by Type (2018-2023)
Figure 32. Global Generic and Biosimilar Pharmaceuticals Market Share Forecast by Type (2024-2029)
Figure 33. Global Generic and Biosimilar Pharmaceuticals Consumption Value Share by Application (2018-2023)
Figure 34. Global Generic and Biosimilar Pharmaceuticals Market Share Forecast by Application (2024-2029)
Figure 35. North America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 36. North America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 37. North America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 39. Canada Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 40. Mexico Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 41. Europe Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 42. Europe Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 43. Europe Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 45. France Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 46. United Kingdom Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 47. Russia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 48. Italy Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Region (2018-2029)
Figure 52. China Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 53. Japan Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 54. South Korea Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 55. India Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 56. Southeast Asia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 57. Australia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 58. South America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 59. South America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 60. South America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 61. Brazil Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 62. Argentina Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 63. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 64. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 65. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 66. Turkey Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 67. Saudi Arabia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 68. UAE Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 69. Generic and Biosimilar Pharmaceuticals Market Drivers
Figure 70. Generic and Biosimilar Pharmaceuticals Market Restraints
Figure 71. Generic and Biosimilar Pharmaceuticals Market Trends
Figure 72. Porters Five Forces Analysis
Figure 73. Manufacturing Cost Structure Analysis of Generic and Biosimilar Pharmaceuticals in 2022
Figure 74. Manufacturing Process Analysis of Generic and Biosimilar Pharmaceuticals
Figure 75. Generic and Biosimilar Pharmaceuticals Industrial Chain
Figure 76. Methodology
Figure 77. Research Process and Data Source
Figure 1. Generic and Biosimilar Pharmaceuticals Picture
Figure 2. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type in 2022
Figure 4. Monoclonal Antibodies
Figure 5. Interferon
Figure 6. Erythropoietin
Figure 7. Insulin
Figure 8. Vaccines
Figure 9. Other
Figure 10. Global Generic and Biosimilar Pharmaceuticals Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 11. Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application in 2022
Figure 12. Tumor Picture
Figure 13. Diabetes Picture
Figure 14. Cardiovascular Picture
Figure 15. Hemophilia Picture
Figure 16. Other Picture
Figure 17. Global Generic and Biosimilar Pharmaceuticals Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 18. Global Generic and Biosimilar Pharmaceuticals Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 19. Global Market Generic and Biosimilar Pharmaceuticals Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 20. Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Region (2018-2029)
Figure 21. Global Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Region in 2022
Figure 22. North America Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Generic and Biosimilar Pharmaceuticals Revenue Share by Players in 2022
Figure 28. Generic and Biosimilar Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 29. Global Top 3 Players Generic and Biosimilar Pharmaceuticals Market Share in 2022
Figure 30. Global Top 6 Players Generic and Biosimilar Pharmaceuticals Market Share in 2022
Figure 31. Global Generic and Biosimilar Pharmaceuticals Consumption Value Share by Type (2018-2023)
Figure 32. Global Generic and Biosimilar Pharmaceuticals Market Share Forecast by Type (2024-2029)
Figure 33. Global Generic and Biosimilar Pharmaceuticals Consumption Value Share by Application (2018-2023)
Figure 34. Global Generic and Biosimilar Pharmaceuticals Market Share Forecast by Application (2024-2029)
Figure 35. North America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 36. North America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 37. North America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 39. Canada Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 40. Mexico Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 41. Europe Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 42. Europe Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 43. Europe Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 45. France Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 46. United Kingdom Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 47. Russia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 48. Italy Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Region (2018-2029)
Figure 52. China Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 53. Japan Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 54. South Korea Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 55. India Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 56. Southeast Asia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 57. Australia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 58. South America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 59. South America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 60. South America Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 61. Brazil Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 62. Argentina Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 63. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Type (2018-2029)
Figure 64. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Application (2018-2029)
Figure 65. Middle East and Africa Generic and Biosimilar Pharmaceuticals Consumption Value Market Share by Country (2018-2029)
Figure 66. Turkey Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 67. Saudi Arabia Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 68. UAE Generic and Biosimilar Pharmaceuticals Consumption Value (2018-2029) & (USD Million)
Figure 69. Generic and Biosimilar Pharmaceuticals Market Drivers
Figure 70. Generic and Biosimilar Pharmaceuticals Market Restraints
Figure 71. Generic and Biosimilar Pharmaceuticals Market Trends
Figure 72. Porters Five Forces Analysis
Figure 73. Manufacturing Cost Structure Analysis of Generic and Biosimilar Pharmaceuticals in 2022
Figure 74. Manufacturing Process Analysis of Generic and Biosimilar Pharmaceuticals
Figure 75. Generic and Biosimilar Pharmaceuticals Industrial Chain
Figure 76. Methodology
Figure 77. Research Process and Data Source
